O	0	2	An	An	DT	B-NP
O	3	11	antibody	antibody	NN	I-NP
O	12	20	directed	direct	VBN	B-VP
O	21	28	against	against	IN	B-PP
O	29	33	PDGF	PDGF	NN	B-NP
O	34	42	receptor	receptor	NN	I-NP
O	43	47	beta	beta	NN	I-NP
O	48	56	enhances	enhance	VBZ	B-VP
O	57	60	the	the	DT	B-NP
B-Cancer	61	70	antitumor	antitumor	NN	I-NP
O	71	74	and	and	CC	O
O	75	78	the	the	DT	B-NP
O	79	83	anti	anti	AFX	I-NP
O	83	84	-	-	HYPH	I-NP
O	84	94	angiogenic	angiogenic	JJ	I-NP
O	95	105	activities	activity	NNS	I-NP
O	106	108	of	of	IN	B-PP
O	109	111	an	an	DT	B-NP
O	112	116	anti	anti	AFX	I-NP
O	116	117	-	-	HYPH	I-NP
O	117	121	VEGF	VEGF	NN	I-NP
O	122	130	receptor	receptor	NN	I-NP
O	131	132	2	2	CD	I-NP
O	133	141	antibody	antibody	NN	I-NP
O	141	142	.	.	.	O

O	143	151	Platelet	Platelet	NN	B-NP
O	151	152	-	-	HYPH	B-PP
O	152	159	derived	derive	VBN	B-NP
O	160	166	growth	growth	NN	I-NP
O	167	173	factor	factor	NN	I-NP
O	174	175	(	(	(	O
O	175	179	PDGF	PDGF	NN	B-NP
O	179	180	)	)	)	O
O	181	184	and	and	CC	O
O	185	188	its	its	PRP$	B-NP
O	189	198	receptors	receptor	NNS	I-NP
O	199	200	(	(	(	O
O	200	205	PDGFR	PDGFR	NN	B-NP
O	205	206	)	)	)	O
O	207	211	play	play	VBP	B-VP
O	212	221	important	important	JJ	B-NP
O	222	227	roles	role	NNS	I-NP
O	228	230	in	in	IN	B-PP
O	231	244	tumorigenesis	tumorigenesis	NN	B-NP
O	245	252	through	through	IN	B-PP
O	253	264	stimulating	stimulate	VBG	B-VP
B-Cancer	265	270	tumor	tumor	NN	B-NP
O	271	277	growth	growth	NN	I-NP
O	278	281	and	and	CC	O
O	282	291	promoting	promote	VBG	B-VP
O	292	304	angiogenesis	angiogenesis	NN	B-NP
O	305	308	via	via	IN	B-PP
O	309	318	enhancing	enhance	VBG	B-VP
B-Cell	319	327	pericyte	pericyte	NN	B-NP
O	328	339	recruitment	recruitment	NN	I-NP
O	340	343	and	and	CC	O
B-Multi-tissue_structure	344	350	vessel	vessel	NN	B-NP
O	351	361	maturation	maturation	NN	I-NP
O	361	362	.	.	.	O

O	363	367	Here	Here	RB	B-ADVP
O	368	370	we	we	PRP	B-NP
O	371	379	produced	produce	VBD	B-VP
O	380	381	a	a	DT	B-NP
O	382	394	neutralizing	neutralize	VBG	I-NP
O	395	403	antibody	antibody	NN	I-NP
O	403	404	,	,	,	O
O	405	408	1B3	1B3	NN	B-NP
O	408	409	,	,	,	O
O	410	418	directed	direct	VBN	B-VP
O	419	426	against	against	IN	B-PP
O	427	432	mouse	mouse	NN	B-NP
O	433	442	PDGFRbeta	PDGFRbeta	NN	I-NP
O	442	443	.	.	.	O

O	444	447	1B3	1B3	NN	B-NP
O	448	453	binds	bind	VBZ	B-VP
O	454	456	to	to	TO	B-PP
O	457	466	PDGFRbeta	PDGFRbeta	NN	B-NP
O	467	471	with	with	IN	B-PP
O	472	476	high	high	JJ	B-NP
O	477	485	affinity	affinity	NN	I-NP
O	486	487	(	(	(	O
O	487	491	9x10	9x10	CD	B-NP
O	491	492	(	(	(	O
O	492	493	-	-	SYM	O
O	493	495	11	11	CD	O
O	495	496	)	)	)	O
O	496	497	M	M	NN	B-NP
O	497	498	)	)	)	O
O	499	502	and	and	CC	O
O	503	509	blocks	block	VBZ	B-VP
O	510	514	PDGF	PDGF	NN	B-NP
O	514	515	-	-	HYPH	O
O	515	517	BB	BB	NN	B-NP
O	518	522	from	from	IN	B-PP
O	523	530	binding	bind	VBG	B-VP
O	531	533	to	to	TO	B-PP
O	534	537	the	the	DT	B-NP
O	538	546	receptor	receptor	NN	I-NP
O	547	551	with	with	IN	B-PP
O	552	554	an	an	DT	B-NP
O	555	557	IC	IC	NN	I-NP
O	557	558	(	(	(	O
O	558	560	50	50	CD	B-NP
O	560	561	)	)	)	O
O	562	564	of	of	IN	B-PP
O	565	578	approximately	approximately	RB	B-NP
O	579	580	1	1	CD	I-NP
O	580	581	.	.	.	I-NP
O	581	582	2	2	CD	I-NP
O	583	585	nM	nM	NN	I-NP
O	585	586	.	.	.	O

O	587	590	The	The	DT	B-NP
O	591	599	antibody	antibody	NN	I-NP
O	600	604	also	also	RB	B-ADVP
O	605	611	blocks	block	VBZ	B-VP
O	612	618	ligand	ligand	NN	B-NP
O	618	619	-	-	HYPH	B-NP
O	619	629	stimulated	stimulate	VBN	I-NP
O	630	640	activation	activation	NN	I-NP
O	641	643	of	of	IN	B-PP
O	644	653	PDGFRbeta	PDGFRbeta	NN	B-NP
O	654	657	and	and	CC	O
O	658	668	downstream	downstream	JJ	B-NP
O	669	678	signaling	signal	VBG	I-NP
O	679	688	molecules	molecule	NNS	I-NP
O	688	689	,	,	,	O
O	690	699	including	include	VBG	B-PP
O	700	703	Akt	Akt	NN	B-NP
O	704	707	and	and	CC	I-NP
O	708	712	MAPK	MAPK	NN	I-NP
O	713	716	p42	p42	NN	I-NP
O	716	717	/	/	SYM	O
O	717	719	44	44	CD	B-NP
O	719	720	,	,	,	O
O	721	723	in	in	IN	B-PP
B-Cell	724	729	tumor	tumor	NN	B-NP
I-Cell	730	735	cells	cell	NNS	I-NP
O	735	736	.	.	.	O

O	737	739	In	In	IN	B-PP
O	740	746	animal	animal	NN	B-NP
O	747	754	studies	study	NNS	I-NP
O	754	755	,	,	,	O
O	756	759	1B3	1B3	NN	B-NP
O	760	773	significantly	significantly	RB	B-ADVP
O	774	782	enhanced	enhance	VBD	B-VP
O	783	786	the	the	DT	B-NP
B-Cancer	787	796	antitumor	antitumor	NN	I-NP
O	797	800	and	and	CC	O
O	801	804	the	the	DT	B-NP
O	805	809	anti	anti	AFX	I-NP
O	809	810	-	-	HYPH	I-NP
O	810	820	angiogenic	angiogenic	JJ	I-NP
O	821	831	activities	activity	NNS	I-NP
O	832	834	of	of	IN	B-PP
O	835	840	DC101	DC101	NN	B-NP
O	840	841	,	,	,	O
O	842	844	an	an	DT	B-NP
O	845	853	antibody	antibody	NN	I-NP
O	854	862	directed	direct	VBN	B-VP
O	863	870	against	against	IN	B-PP
O	871	876	mouse	mouse	NN	B-NP
O	877	885	vascular	vascular	JJ	I-NP
O	886	897	endothelial	endothelial	JJ	I-NP
O	898	904	growth	growth	NN	I-NP
O	905	911	factor	factor	NN	I-NP
O	912	920	receptor	receptor	NN	I-NP
O	921	922	2	2	CD	B-NP
O	922	923	,	,	,	O
O	924	926	in	in	IN	B-PP
O	927	928	a	a	DT	O
B-Cancer	929	939	pancreatic	pancreatic	JJ	O
O	940	941	(	(	(	O
B-Cancer	941	945	BxPC	BxPC	NN	B-NP
I-Cancer	945	946	-	-	HYPH	B-NP
I-Cancer	946	947	3	3	CD	I-NP
O	947	948	)	)	)	O
O	949	952	and	and	CC	O
O	953	954	a	a	DT	B-NP
B-Cancer	955	958	non	non	AFX	I-NP
I-Cancer	958	959	-	-	HYPH	I-NP
I-Cancer	959	964	small	small	JJ	I-NP
I-Cancer	965	969	cell	cell	NN	I-NP
I-Cancer	970	974	lung	lung	NN	I-NP
I-Cancer	975	976	(	(	(	O
I-Cancer	976	979	NCI	NCI	NN	B-NP
I-Cancer	979	980	-	-	HYPH	B-NP
I-Cancer	980	984	H460	H460	NN	I-NP
I-Cancer	984	985	)	)	)	O
I-Cancer	986	991	tumor	tumor	NN	B-NP
I-Cancer	992	1001	xenograft	xenograft	NN	I-NP
O	1002	1008	models	model	NNS	I-NP
O	1008	1009	.	.	.	O

O	1010	1019	Treatment	Treatment	NN	B-NP
O	1020	1024	with	with	IN	B-PP
O	1025	1028	the	the	DT	B-NP
O	1029	1040	combination	combination	NN	I-NP
O	1041	1043	of	of	IN	B-PP
O	1044	1047	1B3	1B3	NN	B-NP
O	1048	1051	and	and	CC	I-NP
O	1052	1057	DC101	DC101	NN	I-NP
O	1058	1060	in	in	IN	B-PP
B-Cancer	1061	1065	BxPC	BxPC	NN	B-NP
I-Cancer	1065	1066	-	-	HYPH	O
I-Cancer	1066	1067	3	3	CD	B-NP
I-Cancer	1068	1077	xenograft	xenograft	NN	I-NP
O	1077	1078	-	-	HYPH	B-PP
O	1078	1085	bearing	bear	VBG	B-NP
O	1086	1090	mice	mouse	NNS	I-NP
O	1091	1099	resulted	result	VBD	B-VP
O	1100	1102	in	in	IN	B-PP
B-Cancer	1103	1108	tumor	tumor	NN	B-NP
O	1109	1119	regression	regression	NN	I-NP
O	1120	1122	in	in	IN	B-PP
O	1123	1125	58	58	CD	B-NP
O	1125	1126	%	%	NN	I-NP
O	1127	1129	of	of	IN	B-PP
O	1130	1134	mice	mouse	NNS	B-NP
O	1135	1143	compared	compare	VBN	B-VP
O	1144	1146	to	to	TO	B-PP
O	1147	1151	that	that	DT	B-NP
O	1152	1154	in	in	IN	B-PP
O	1155	1157	18	18	CD	B-NP
O	1157	1158	%	%	NN	I-NP
O	1159	1161	of	of	IN	B-PP
O	1162	1166	mice	mouse	NNS	B-NP
O	1167	1174	treated	treat	VBN	B-VP
O	1175	1179	with	with	IN	B-PP
O	1180	1185	DC101	DC101	NN	B-NP
O	1186	1191	alone	alone	RB	B-ADVP
O	1191	1192	.	.	.	O

O	1193	1198	Taken	Take	VBN	B-VP
O	1199	1207	together	together	RB	B-ADVP
O	1207	1208	,	,	,	O
O	1209	1214	these	these	DT	B-NP
O	1215	1222	results	result	NNS	I-NP
O	1223	1227	lend	lend	VBP	B-VP
O	1228	1233	great	great	JJ	B-NP
O	1234	1241	support	support	NN	I-NP
O	1242	1244	to	to	TO	B-VP
O	1245	1248	use	use	VB	I-VP
O	1249	1258	PDGFRbeta	PDGFRbeta	NN	B-NP
O	1259	1270	antagonists	antagonist	NNS	I-NP
O	1271	1273	in	in	IN	B-PP
O	1274	1286	combinations	combination	NNS	B-NP
O	1287	1291	with	with	IN	B-PP
O	1292	1297	other	other	JJ	B-NP
B-Cancer	1298	1307	antitumor	antitumor	NN	I-NP
O	1308	1311	and	and	CC	O
O	1311	1312	/	/	SYM	B-NP
O	1312	1314	or	or	CC	O
O	1315	1319	anti	anti	AFX	O
O	1319	1320	-	-	HYPH	O
O	1320	1330	angiogenic	angiogenic	JJ	B-NP
O	1331	1337	agents	agent	NNS	I-NP
O	1338	1340	in	in	IN	B-PP
O	1341	1344	the	the	DT	B-NP
O	1345	1354	treatment	treatment	NN	I-NP
O	1355	1357	of	of	IN	B-PP
O	1358	1359	a	a	DT	B-NP
O	1360	1367	variety	variety	NN	I-NP
O	1368	1370	of	of	IN	B-PP
B-Cancer	1371	1378	cancers	cancer	NNS	B-NP
O	1378	1379	.	.	.	O

